VarCov Co’s Intellia Therapeutics NTLA Stock Holding History

VarCov Co’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-29,109	Closed	-$262K	–	550
2025 Q4	$262K	Buy	+29,109	New	+$401K	0.1%	330

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

VarCov Co's NTLA Position: Q1 2026 in Review

VarCov Co sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 29,109 shares — an estimated $262K sold.

VarCov Co first reported a position in NTLA in Q4 2025 and held it in 1 quarter. The position peaked at $262K in Q4 2025. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

VarCov Co reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
VarCov Co sold 29,109 Intellia Therapeutics shares in Q1 2026, an estimated $262K.
VarCov Co first reported a position in Intellia Therapeutics in Q4 2025 and held it in 1 quarter.
VarCov Co's Intellia Therapeutics position peaked at $262K in Q4 2025.
303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on VarCov Co's 13F filing for Q1 2026, filed 15 May 2026.